About Us
Based in Hong Kong, we are home to some of the world’s most ...
Our Product
Product introduction
Our Research
Prohep for the prevention and treatment of HCC
Zero Plus Based in Hong Kong, we are home to some of the world’s most intrepid scientists from the world’s top university, with a proven track record of success in drug discovery and development.
In the later stage, our products are targeting hyperlipidemia, non-alcoholic fatty liver disease, children’s anti-allergy, etc.
Zero Plus's mission is to contribute to the health and happiness of every person around the world through the pursuit of excellence in life sciences and the study of microorganisms.
Prohep is the world's first novel microbiological agent for the prevention and treatment of liver cancer. It was developed by a team led by Dr. Hani EI-Nezami and Gianni Panagiotou from the Department of Biology at the University of Hong Kong, in collaboration with the Li Ka Shing School of Medicine at the University of Eastern Finland.
The research results were published in PNAS (Proceedings of the National Academy of Sciences) in March 2016. The team applied for patents through HKU Technology Transfer Office - HKU Keqiao Company, and has been awarded US, China and Greater Europe patents.
Phone:13916994671 Email:info@zeroplusltd.com
